000880228 001__ 880228
000880228 005__ 20230207130606.0
000880228 0247_ $$2CORDIS$$aG:(EU-Grant)882295$$d882295
000880228 0247_ $$2CORDIS$$aG:(EU-Call)H2020-SMEInst-2018-2020-1$$dH2020-SMEInst-2018-2020-1
000880228 0247_ $$2originalID$$acorda__h2020::882295
000880228 035__ $$aG:(EU-Grant)882295
000880228 150__ $$aA long-acting, constant release ocular implant for the sustained delivery of biologics and small molecules for the treatment of retinal diseases.$$y2019-11-01 - 2020-02-29
000880228 371__ $$aMICROSERT LTD$$bMICROSERT LTD$$dIsrael$$ehttp://www.microsert.com$$vCORDIS
000880228 372__ $$aH2020-SMEInst-2018-2020-1$$s2019-11-01$$t2020-02-29
000880228 450__ $$aBlueDot$$wd$$y2019-11-01 - 2020-02-29
000880228 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000880228 680__ $$aSeventy-six million people will suffer from blindness by 2020. Age-related retinal disorders - macular degeneration (AMD) and diabetic macular edema (DME) are two of the leading causes of blindness in the world. About 200,000 new cases of advanced, age-related AMD identified each year in the United States and between 14.9 and 21.5 million cases of early AMD, and between 3.9 and 4.8 million cases of late AMD is expected in Europe by 2040. The complexity of eye anatomy presents challenges for treatment. Current treatment, intravitreal injections (IVI) are the highest growth medical procedure in the globe, with an estimated 20 million intravitreal injections globally in 2016. Ranibizumab, treatment blocking vascular endothelial growth factor (VEGF), which promotes blood vessel growth, costs approximately $2,000 in USA and €1000 per injection. Patients may need up to 12 injection per year. Additionally, this treatment significantly affects patient comfort.
MicroSert has developed BlueDot – a novel, long-acting release (LAR) ocular implant for the sustained delivery of biologics and small molecules for the treatment of retinal diseases. BlueDot is implantable to the tear duct and releases therapeutic inside the eye. Implantation requires one-step office-based procedure using proprietary implantation device with safety monitoring system and with no incision needed. BlueDot is refillable and lasts up to two years.
The SME-I Phase 1 project perfectly suits the innovation’s current stage of development and overall business strategy allowing MicroSert to check final specifications of BlueDot, establish a sound business development and gain partners necessary for the Phase II study.
000880228 909CO $$ooai:juser.fz-juelich.de:880228$$pauthority$$pauthority:GRANT
000880228 970__ $$aoai:dnet:corda__h2020::aa27a57d69d1b0955bd520ca98182072
000880228 980__ $$aG
000880228 980__ $$aCORDIS
000880228 980__ $$aAUTHORITY